Sociedad Americana de Hirudoterapia

Saudi Food and Drug Authority

SFDA · Saudi Arabia · middle east

Regulatory jurisdiction profileJurisdictional reference
Medical device clearednational regulator

Saudi Arabia's SFDA — leech therapy supervised under medical-device pathway, with Saudi Vision 2030 expansion of traditional/complementary medicine via NCCAM-KSA at the Ministry of Health.

Regulatory Profile

Agency type
national regulator
Region
middle east
Country
Saudi Arabia
Leech status
medical device cleared
Last ASH review
2026-05-25

Relevant Regulation Codes

  • Royal Decree No. M/6 of 1428H — SFDA establishment
  • Medical Devices Interim Regulation, MDS-REQ 1 (2020 revision)
  • Saudi MoH NCCAM (National Center for Complementary and Alternative Medicine) guidance

Prescriber Requirements

  • Saudi Commission for Health Specialties (SCFHS)-registered MD
  • Nurses (SCFHS-registered) under physician's order
  • Hijama practitioners require separate NCCAM certification under MoH; leech therapy increasingly offered alongside Hijama in NCCAM-licensed clinics

Supply Chain & GMP

SFDA Medical Device Marketing Authorisation (MDMA); Saudi Authorised Representative required. Bilingual Arabic/English labelling.

Import/Export Rules

SFDA import licence + Ministry of Environment, Water and Agriculture (MEWA) clearance for live invertebrates. CITES via Saudi Wildlife Authority.

Reimbursement Context

Council of Cooperative Health Insurance (CCHI) governs the Cooperative Health Insurance Law — inpatient flap-salvage covered. NCCAM-licensed outpatient hirudotherapy / hijama services expanding under Vision 2030.

Key Regulatory Documents

  1. Medical Devices Interim Regulation MDS-REQ 1 (2020)

ASH Editorial Notes

Saudi Arabia's prophetic-medicine framework (Tibb Nabawi) gives leech therapy a culturally embedded position; the 2014 NCCAM-KSA programme and Vision 2030 health-transformation pillar expand institutional support.

Related Jurisdictions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.